Seres Therapeutics, Inc. Cash Flow Statement
MCRB|10 years of annual SEC 10-K data (FY2015-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$117M
FY2025
Free Cash Flow
-$125M
FY2025
Capital Expenditures
$8M
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Seres Therapeutics, Inc. used $117M in operating cash flow and negative free cash flow of $125M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$113.7M | -$65.6M | -$89.1M | -$70.3M | -$98.9M | -$89.4M | -$91.6M | -$54.8M | -$16.7M | -$6.1M |
| Depreciation & Amortization | $6.2M | $5.9M | $6.6M | $7.6M | $7.9M | $7.3M | $4.2M | $728.0K | $190.0K | $88.0K |
| Operating Cash Flow | -$117.4M | $6.7M | -$93.6M | -$76.5M | -$62.9M | -$75.5M | $43.9M | -$40.8M | -$10.4M | -$5.3M |
| Capital Expenditures | $8.0M | $9.6M | $591.0K | $1.0M | $1.9M | $4.7M | $21.5M | $4.4M | $1.0M | $174.0K |
| Free Cash Flow | -$125.3M | -$2.9M | -$94.2M | -$77.5M | -$64.8M | -$80.2M | $22.4M | -$45.2M | -$11.4M | -$5.5M |
| Share Buybacks | - | - | - | - | - | - | - | $33.0K | - | - |
| FCF Margin | - | -2.0% | -283.6% | -224.7% | -229.2% | -249.8% | 103.0% | -207.7% | -52.2% | - |